<DOC>
	<DOC>NCT01901185</DOC>
	<brief_summary>The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (EnbrelÂ®).</brief_summary>
	<brief_title>Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept</brief_title>
	<detailed_description>Study participants need to have been self-administering etanercept for greater than or equal to 6 months prior to screening. You will be in this study for about 9 weeks. This includes a 4-week screening period and a 5-week treatment period.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject has diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on history. Subject is willing to selfinject per investigator judgement at screening. Subject has no known history of tuberculosis. Latex allergy. Subject has any active infection (including chronic or localized infections) for which antiinfectives were indicated within 4 weeks prior to first study dose of etanercept. Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening. Other criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>